Hebb AL, Sawynok J, Bance M, Walling S, Chisholm K, Morris DP. Pharmacological management of neuropathic pain in patients with vestibular schwannomas: Experience of the Atlantic Lateral Skull Base Clinic. World J Pharmacol 2014; 3(2): 24-32 [DOI: 10.5497/wjp.v3.i2.24]
Corresponding Author of This Article
Dr. Andrea LO Hebb, MSc, PhD, RN, Capital District Health Authority, QEII Halifax Infirmary Site, 3rd Floor, Division of Neurosurgery, 1796 Summer Street, Halifax NS B3H 3A7, Canada. firstname.lastname@example.org
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Pharmacological management of neuropathic pain in patients with vestibular schwannomas: Experience of the Atlantic Lateral Skull Base Clinic
Andrea LO Hebb, Jana Sawynok, Manohar Bance, Simon Walling, Ken Chisholm, David P Morris
Andrea LO Hebb, Atlantic Lateral Skull Base Clinic, Division of Neurosurgery, Dalhousie University, QEII Halifax Infirmary Site, Halifax NS B3H 3A7, Canada
Andrea LO Hebb, Capital District Health Authority, QEII Halifax Infirmary Site, 3rd Floor, Division of Neurosurgery, Halifax NS B3H 3A7, Canada
Jana Sawynok, Department of Pharmacology, Dalhousie University, Nova Scotia B3H 4R2, Canada
Manohar Bance, David P Morris, Division Otolaryngology, Dalhousie University, QEII Health Sciences Centre, Halifax NS B3H 2Y9, Canada
Simon Walling, Division of Neurosurgery, Dalhousie University, Halifax Infirmary Site, QEII Health Sciences Centre, Halifax NS B3H 3A7, Canada
Ken Chisholm, Department of Anesthesia and Pain Management, Dalhousie University, Halifax NS B3H 2Y9, Canada
ORCID number: $[AuthorORCIDs]
Author contributions: All authors had contributed substantially to conception and design, or acquisition of data, or analysis and interpretation of data; drafted the article or revised it critically for important intellectual content and gave final approval of the version to be published.
Correspondence to: Dr. Andrea LO Hebb, MSc, PhD, RN, Capital District Health Authority, QEII Halifax Infirmary Site, 3rd Floor, Division of Neurosurgery, 1796 Summer Street, Halifax NS B3H 3A7, Canada. email@example.com
Telephone: +1-902-473-4824 Fax: +1-902-425-4176
Received: April 29, 2014 Revised: May 31, 2014 Accepted: June 5, 2014 Published online: June 9, 2014
Neuropathic pain is chronic pain generated by disorders of the peripheral and central nervous system, including skull base tumours. A skull base tumour can be any type of tumour that forms in the skull base, and this includes vestibular schwannomas which arise from the sheath of the inner ear vestibulocochlear nerve (eighth cranial nerve). Growth of the tumour, surgical resection, and/or stereotactic radiotherapy may result in compression and/or irritation of the fifth cranial nerve (trigeminal nerve) resulting in facial pain and/or numbness. Non-trigeminal afferent input may contribute to the wide constellation of symptoms seen in orofacial pain patients. The purpose of this report was to develop a decision tool to guide the recognition and treatment of neuropathic pain in this specialized population. Recommendations for treatment are based on evidence presented in Canadian and international neuropathic treatment guidelines. Algorithms are included for assessment and treatment of adult patients with agents that are recognized to have analgesic efficacy within the broad context of neuropathic pain.
Core tip: The complexity of managing trigeminal neuralgia and neuropathic pain conditions among patients with skull base tumors requires a simple albeit comprehensive treatment algorithm that can be employed effectively by general practitioners, surgeons and other primary care prescribers in acute care or ambulatory clinical settings. We describe a simple treatment algorithm formulated on recommended best practice and based on clinical experience. It is intended to guide treatment, facilitate management and evaluation of outcome data (self-reported pain, quality of life measures) to elucidate the use of standardized approaches to pain management in patients with skull base etiology.
Citation: Hebb AL, Sawynok J, Bance M, Walling S, Chisholm K, Morris DP. Pharmacological management of neuropathic pain in patients with vestibular schwannomas: Experience of the Atlantic Lateral Skull Base Clinic. World J Pharmacol 2014; 3(2): 24-32
This report considers pharmacological approaches to be used within the skull base tumour health community. Its intent is to offer assistance in treating patients who present with neuropathic pain (NP) in the context of orofacial, head and neck pain, including trigeminal neuralgia (TN), which is the most common craniofacial pain syndrome that is neuropathic in origin. The impetus for assembling the information stems from the experiences of practitioners within an interdisciplinary clinic who consistently rely on formularies and consultation with colleagues for advice in treating neuralgia and NP. The document offers suggested algorithms for assessment and treatment of patients with agents that are recognized to have analgesic efficacy within the broader context of NP. It makes the distinction between generalized NP and NP due to skull base tumours affecting the head, neck, face and glossopharyngeal region[2,3], but also recognizes commonalities in mechanisms underlying various forms of NP.
The Atlantic Lateral Skull Base Clinic
Vestibular schwannomas (VS) are slow growing, benign neoplasms that may be life threatening due to compression of central structures. Extra-axial tumours arising from the Schwann cell sheath of the vestibular or cochlear nerve (8th cranial nerve) are referred to as acoustic neuromas or, more appropriately, VS. Clinical diagnosis of a VS suggests an incidence of 0.7-1 per 100000 people, although incidental (i.e., non-clinically relevant) discovery of VS suggests an incidence as high as 2 per 10000 people. In some cases, VS are associated with NP and TN, often secondary to tumour compression or stereotactic radiation treatment affecting cranial nerves within the cerebellopontine angle (CPA).
The Atlantic Lateral Skull Base Clinic provides coordinated care through Neurootology (Division of Otolaryngology), Neurosurgery and the Stereotactic Radiotherapy Group to patients with unilateral or bilateral VS, other CPA tumours, as well as lesions of the petrous apex and jugular foramen. This program is unique in Canada, offering a single centre, multidisciplinary approach for lateral skull base lesions. The Atlantic Lateral Skull Base Clinic serves a population of more than 2 million people in a catchment area that includes Newfoundland, Prince Edward Island, New Brunswick and Nova Scotia. Treatment options for skull base tumours include monitoring clinical progression, surgery, stereotactic radiation therapy (SRT), balance and hearing rehabilitation. An interdisciplinary clinic provides an ideal environment in which to identify and intervene in the treatment and management of NP affecting the head and neck region. The focus of this work is on clinical experiences within our clinic. With low incidence, it will be very unlikely there will ever be randomized clinical trials that provide direct guidance for pain management in patients with VS. In that event, one must rely on extrapolation, and what we report is implementation of that approach and what it looks like in clinic.
NP is a chronic pain state that is initiated by peripheral and central nervous system injury caused by trauma, inflammation, infection or metabolic disease, and includes conditions such as distal polyneuropathy due to diabetes [diabetic neuropathy (DN)] and post-herpetic neuralgia (PHN). The Canadian Pain Society (CPS) estimates (based on 8.2% chronic NP prevalence in the general population) that 1 million Canadians live with NP[6-8]. Neuropathic pain interferes with activities of daily living and work performance, impairs mood, decreases quality of living and generates three-fold increases in health care costs relative to matched controls. NP conditions involve spontaneous (paroxysmal or ongoing) and stimulus-evoked (e.g., mechanical and thermal) symptoms; continuous or intermittent spontaneous pain is frequently described as burning, stabbing, shooting or shock-like; stimulus-evoked pain includes allodynia (pain in response to non-painful stimulation, extreme sensitivity to touch) and hyperalgesia (enhanced response to painful stimuli); NP can also involve tingling and numbness[1,6,9].
TN involves irritation or compression of the 5th cranial nerve (trigeminal nerve), which evokes paroxysmal episodic stabbing pain of the facial area. Classically, pain is described as a sharp, shooting, electric shock-like, unilateral pain with acute onset and termination in distribution of the trigeminal nerve; this usually involves the V2 (maxillary) and V3 (mandibular) divisions but is rare in the V1 (ocular) division. TN has an incidence of 4-28 per 100000 person years[11,12]. It can arise due to vascular alterations, non-vascular lesions, or tumours and other skull base abnormalities which exert pressure on the trigeminal nerve located in the CPA. Trigeminal NP is more continuous, and is characterized as burning, aching, throbbing. VS, or acoustic neuromas, are the most frequent CPA tumour to cause TN-like symptoms. Non-trigeminal nociceptive input, concurrent with induced masticatory responses (i.e., hypoglossal, spinal accessory, facial, glossopharyngeal and vagal motor centers), may contribute to the wide constellation of symptoms seen in orofacial pain patients. The distinction between TN and trigeminal NP is important, as there are different treatment recommendations for each[1,10].
Treatment guidelines and decision rules improve patient outcomes. Recent literature providing strategies for the treatment of NP include the consensus statement and guidelines from the CPS, as well as the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain[15,16]. It needs to be emphasized that most recommendations have been derived from studies on PHN and DN. The European Federation of Neurological Societies (EFNS) Task Force included an approach to the management of NP pain associated with damage to the trigeminal nerve.
There remains a paucity of information on how to assess, diagnose and treat pain in patients with VS or other skull base tumours, pain that appears to be of neuropathic origin and typically resides within the head, face, neck and glossopharyngeal area. In order to provide guidance relating to this specialized patient population, we constructed an algorithm for NP and craniofacial pain, including TN, based on Canadian contemporary standards of care and existing NP treatment algorithms. Recommendations consider pharmaceutical agents with evidence of efficacy in neuropathic pain, patient tolerability of the dose range expected to be needed, and actual therapeutic efficacy observed within our clinical practice. To date, there has not been a published tool that provides a clearly-defined algorithm for the assessment and treatment of NP in patients with skull base tumours. It is intended that this report provides guidance to primary care practitioners treating NP in patients with skull base tumours, using specific drugs or combinations of drugs, to improve outcomes in clinical practice with respect to patient self-reports of pain and quality of life.
CHARACTERIZATION OF PAIN ASSOCIATED WITH SKULL BASE TUMOURS
Skull base tumours involve the proliferation of abnormal cells in the part of the brain that meets the base of the skull. Symptoms of skull base tumours may include twitching, paralysis or facial pain. Craniofacial NP disorders include neuropathies, neuromas and neuralgias. Although significant interpractitioner and institutional variability exists, facial neuropathy and trigeminal nerve disturbances are relatively uncommon in comparison with unilateral hearing loss, tinnitus and vertigo or even idiopathic headache[18,19]. Even if uncommon, when a patient presents with what appears to be NP, the origin of the pain and appropriate treatment actions may be more difficult to determine than the existence of pain. At the very least, the challenge is to identify where the pain is coming from and to distinguish it from idiopathic headaches. Headaches are present in 50%-60% of patients with unilateral VS at the time of diagnosis[4,20]. Clinically, headaches that are unresponsive to over-the-counter analgesics may be a subtle cue that the pain originates from compression of the cranial nerves by the tumour. It has been reported that 3% to 45% of patients with CPA VS experience facial paresis, facial neuropathy and trigeminal nerve disturbances (hypoesthesia, paresthesia, and neuralgia) due to compression by the tumour on the ipsilateral[13,22], and less commonly, on contralateral cranial nerves; up to 93% are at risk secondary to irradiation treatment[24-27].
The incidence of pain following SRT treatment is common. It has been estimated that 93% of lesions treated with SRT leave the patient at risk of radiation-induced TN. Other centers report that trigeminal symptoms occur in ≥ 3% of patients whose tumours approach the level of the trigeminal nerve. It is also important to distinguish NP from pain associated with hydrocephalus which may occur following tumour irradiation. As such, patients presenting with pain should be referred for a magnetic resonance imaging (MRI) or computerized tomography scan. It is evident, given the diversity of pain mechanisms and individual patient responses that no single drug works for all NP states. In this respect, successful management of pain syndromes first necessitates accurate assessment.
PHARMACOLOGICAL MANAGEMENT OF NEUROPATHIC PAIN
Assessment of pain and associated symptoms is necessary for diagnosis and management of NP. The self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs scale and the French Neuropathic Pain Group clinician-administered questionnaire called DN4 may be used, based on their high sensitivity and selectivity[1,28,29]. The use of these tools is meant to complement but not replace clinical judgment.
Current treatment guidelines provide an evidence-based approach to the treatment of NP. Treatment guidelines have been developed based on data collected from randomized controlled clinical trials of anticonvulsants (carbamazepine, oxcarbazepine), tricyclic antidepressants (TCAs) (amitriptyline, nortriptyline), serotonin-norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), calcium channel ligands (gabapentin, pregabalin), local anesthetics (5% lidocaine patch), opioids (morphine, methadone) and opioid-like hybrid drugs (tramadol)[6,16,17]. It should be mentioned that if the 5% lidocaine patch is unavailable, a lidocaine gel formulation or compounded cream may be substituted, although limited efficacy in non-post-herpetic pain has been reported. A general overview of our suggested algorithm for the management of NP in our clinic is presented in Figures 1 and 2.
Figure 1 Assessment and management of neuropathic pain.
NP: Neuropathic pain; PTSS: Pain treatment satisfaction scale.
Figure 2 Management of neuropathic pain or trigeminal neuralgia in the Atlantic Lateral Skull Base Clinic.
NP: Neuropathic pain; TN: Trigeminal neuralgia; SNRI: Serotonin-norepinephrine reuptake inhibitor.
The algorithms presented below are based on published clinical guidelines to simplify the management and evaluation of NP in patients with lateral skull base tumours. Suggested first, second and third line agents [determined by efficacy, indicated by number-needed-to-treat (NNT), and patient tolerability as indicated by number-needed-to-harm (NNH), or side-effects] are listed in Figure 3. NNT and NNH vary according to the etiology of the pain and reference consulted[31,32]. Algorithms for individual pharmacological agents include initial starting doses, titration doses, temporal intervals and maximal dosing schedules. In addition, TCAs, SNRIs, gabapentinoids, opioid analgesics and tramadol must all be used with caution in elderly patients because of the risk of falls and cognitive impairment[15,16]. Recommendations are also made regarding the duration of adequate trials at maximum tolerated dosages to evaluate the impact on self-reported pain.
For management of classical TN (characterized by paroxysmal, unilateral pain), carbamazepine is the first choice, but otherwise it is not used; this agent has a NNT around 1.9 with virtually complete pain relief[6,10,34-36] (Table 1). Oxcarbazepine can, and should, be substituted for carbamazepine if there is an unacceptable side effect profile[10,34-36] (Table 1).
Table 1 Summary of drugs used for management of trigeminal neuralgia and neuropathic pain.
300-1000 mg; 100 mg BID initially, increase by 200 mg weekly Adequate trial 8-12 wk, 2 wk at maximal dose
Drowsiness, ataxia, headaches, nausea, vomiting, constipation, blurred vision, rash Drug interactions Taper doses when discontinuing
Keto derivative of CBZ, same actions
Equivalent efficacy to CBZ; 300-2400 mg; 300 mg BID initially, increase by 600 mg weekly Adequate trial 8-12 wk, 2 wk at maximal dose
Improved tolerability compared to CBZ Vertigo, fatigue, dizziness, nausea, hyponatraemia in high doses No major drug interactions Taper doses when discontinuing
TCAs or tricyclic antidepressants: nortriptyline, amitriptyline
Block NA and 5-HT reuptake, block Na+ channels, interact with several neurotransmitter systems
Nortriptyline 10 mg (elderly) or 25 mg (adult) at bedtime; increase dose by 10 or 25 mg every 3-7 d; up to 75-100 mg daily Adequate trial 6-8 wk, 2 wk at maximal dose Amitriptyline doses similar
Nortriptyline is better tolerated than amitriptyline Dry mouth, constipation, blurred vision, sedation, orthostatic hypotension Taper doses when discontinuing
SNRIs or serotonin-noradrenaline reuptake inhibitors: Duloxetine, Venlafaxine
Similar actions to TCAs, but fewer interactions with receptor systems
Duloxetine: 60 mg/d, increase to 120 mg after 1 wk Venlafaxine: 75 mg/d, increase to 225 mg over 3 wk Adequate trial 4-6 wk, 2 wk at maximum dose
Headache, nausea, dry mouth, sleepiness, fatigue, constipation, dizziness, decreased appetite, and increased sweating. Taper doses when discontinuing Drowsiness, dizziness, weakness, feeling nervous, tinnitus, increased sweating, blurred vision, dry mouth, changes in appetite or weight, facial flushing, mild nausea, constipation, sexual side-effects Taper doses over 7-10 d when discontinuing
Ca2+ channel modulator
100-300 mg TID, increase dose every 1-7 d; maximum dose 3600 mg daily Adequate trial 3-8 wk titration, 2-8 wk at maximal dose
Dizziness, sedation, weight gain, weakness, tiredness, nausea, diarrhea, constipation, blurred vision, headache, breast swelling, dry mouth, fatigue, myalgia, loss of balance or coordination Taper doses when discontinuing
Ca2+ channel modulator
50 mg OD or 25 mg BID, double dose each week; maximum daily dose 600 mg Adequate trial is 4 wk at maximal dose
Dizziness, drowsiness, loss of balance or coordination, problems with memory or concentration, anxiety, depersonalization, hypertonia, hypesthesia, decreased libido, nystagmus, paresthesia, twitching, breast swelling, tremors, dry mouth, constipation Taper doses when discontinuing (minimum of one week)
Inhibits NA and 5-HT reuptake, binds opioid receptors
50 mg BID, increase by 50-100 mg daily in divided doses over 3-7 d as tolerated; 400 mg is maximum dose (300 mg in elderly) Adequate trial is 4 wk at maximum dose
1These are not a complete list of side effects and others may occur. CBZ: Carbamazepine; 5-HT: Serotonin; NA: Noradrenaline; OXC: Oxcarbazepine; q4h: Every four hours; BID: Twice a day; TCA: Tricyclic antidepressant; SNRI: Serotonin-norepinephrine reuptake inhibitors; prn: Pro re nata; TID: Three times a day; OD: Once daily; CR: Continuous release.
For management of NP, there are several TCAs available, but amitriptyline and nortriptyline are commonly used, and exhibit NNT values of 1.3-3.6[32,37-39]; NNH values are 3-6 for minor, and 14-28 for major, harm. The analgesic properties of TCAs are independent of their antidepressant effects, and several mechanisms, in addition to blockage of serotonin and norepinephrine reuptake, are involved in their actions. It should be emphasized that caution must be employed with the use of TCAs in older patients because of anticholinergic adverse effects, sedation, risk of falls, and risk of cardiac toxicity. Nortriptyline, a metabolite of amitriptyline with similar pharmacological effectiveness reflected in similar NNT values[6,37,39], has a lower incidence of adverse effects compared to amitriptyline[32,41]. The lowest effective dose of TCA should be used in NP patients, avoiding patients with ischemic heart disease or increased risk of cardiac death (Table 1). Where available, lidocaine medicated plaster (NNT = 4.4, NNH = 29), a topical formulation, can be considered first-line treatment if the pain is focal and there are tolerability issues for oral formulations[16,37].
The EFNS and Neuropathic Pain Special Interest Group (NeuPSIG) recommend the two SNRIs, duloxetine and venlafaxine, as first-line options, while Canadian guidelines consider these second-line options for treatment of NP. Duloxetine (NNT = 5-6; NNH = 7-9 minor, 13-15 major) has primarily been examined in DN, while venlafaxine (NNT = 3-5, NNH = 7-9 minor, 16 major) has been examined in a broader range of NP conditions[31,37-39] (Table 1). Venlafaxine may be employed in combination with gabapentin to increase its efficacy[16,30,42,43].
The Consensus Statement and Guidelines from the Canadian Pain Society list gabapentin and pregabalin as first-line agents in the treatment of NP. Most of the literature and guidelines for NP are based on PHN and DN and may not be applicable to all NP conditions[9,15]. Gabapentin (NNT = 4.1-6.4, NNH = 3.7) and pregabalin (NNT = 3.3-6.0, NNH = 3.7-8.8) (Table 1)[32,37,38] can be considered as first- or second-line agents for management of orofacial NP associated with skull base tumours. The EFNS Task Force has identified the usefulness of combination therapy, including TCA-gabapentin for the management of NP and TN (Figure 2).
Gabapentin and pregabalin decrease the release of several neurotransmitters involved in pain through binding to the α2-δ subunit of voltage-gated calcium channels, synaptic γ-aminobutyric acid modulation and synaptogenesis. Side effects of gabapentin include dry mouth, dizziness, gastrointestinal disturbances and cognitive impairment. There is some evidence that the efficacy of gabapentin is increased in painful DN, when combined with venlafaxine or morphine[31,45]. Combination of gabapentin with nortriptyline was superior to either drug alone, and combination of gabapentin with opioids has shown increased efficacy for the treatment of TN and NP (Figure 2).
Tramadol, a hybrid drug with SNRI and μ-opioid agonist properties, has a NNT = 3.4-4.9, and a NNH = 7.7; it should not be combined with TCAs due to increased risk of serotonin syndrome[32,37] (Table 1). Opioids are generally safe if titrated slowly. While there is some evidence to support opioids in NP[15,32,37,39], opioids as primary therapy are not always effective, and combination therapy may be needed[31,42,44]. The analgesic efficacy of a combination of morphine and gabapentin was increased compared to each individual agent in patients with PHN and painful DN; however, while the maximal tolerated doses were lower in combination therapy, there was report of increased adverse effects.
There are many liabilities and controversies surrounding the use of opioids in those with chronic non-cancer pain[28,46]. For treating NP with opioids we follow recommendations of the 2010 National Opioid Use Guideline Group; referral to a chronic pain service is indicated when combination therapies involve primary and adjuvant treatment beyond the common agents listed.
Although beyond the scope of this document and better reserved for pain specialty clinics, interventional procedures, compounded drugs (such as carbamazepine, gabapentin, antidepressants, lidocaine) delivered as topical formulations for the orofacial region, invasive techniques (may include intravenous lidocaine) or intradermal botulinum toxin may be considered. Several recent case series reports and a controlled study support the efficacy and safety of botulinum toxin for TN[48-50]. Future treatment guidelines will position these options within current schemes.
Two case examples of the presentation and treatment of neuropathic pain resulting from VS are outlined below.
Presentation and diagnosis: RG, a 72-year-old retired fireman, presented to the Atlantic Lateral Skull Base Clinic in August 2010 with progressive right-sided hearing loss and tinnitus over 1-2 years with a new presentation of numbness and tingling on the right side of his face including the tip of his tongue. MRI revealed a right-sided cerebellar pontine angle tumour (25 mm × 27 mm) in the axial plane with mass effect on the brainstem consistent with a vestibular schwannoma/acoustic neuroma. RG opted for stereotactic radiation therapy (SRT) over surgery or a more conservative “wait and scan” approach.
Symptoms prior to treatment: In December 2010, prior to SRT therapy, lidocaine hydrochloride swish and spit was ineffective in controlling symptoms. In January 2011, he reported exacerbation of symptoms on the right side of his face, dysesthesia rather than numbness, constant burning involving the tip of the tongue and the bottom of the tongue on the right hand side; symptoms were exacerbated by eating. He had lost 30 pounds due to decreased food intake. Pregabalin 75 mg twice a day and dexamethasone 4 mg every morning with breakfast was prescribed. Over the next month, pregabalin was increased to 150 mg twice a day as he noted some early improvement. The pregabalin dose was again increased to 300 mg and RG gained 3 pounds.
Treatment and follow up: SRT began in February 2011. RG noticed an immediate improvement in his tinnitus. In March 2011, gabapentin replaced pregabalin and was increased to 1800 mg/d while dexamethasone weaning began. RG experienced hypotension in response to the increase in gabapentin and the dose was decreased to 300 mg three times a day. SRT was completed in April 2011. At this time, RG reported increased facial pain, so gabapentin was increased to 1200 and then 1500 mg/d. RG was not reporting any relief from symptoms, and numbness and right-sided trigeminal neuralgia persisted. In October 2011, he was weaned off gabapentin, and amitriptyline was prescribed for facial pain 10 mg every night, and increased to 20 mg after 1 wk. In November 2011, he reported side effects which included sleepiness and nausea. His family doctor changed the prescription to nortriptyline 10 mg for 5 d, then 20 mg/d for 5 d, and then 30 mg/d, with a plan to increase this again in the next 5 d to 50 mg/d, his current dose in February 2012. He has improved facial pain and reports improvements in eating and tasting food. He still has some paresthesia and dysesthesia in the right side of his face in the trigeminal distribution in all 3 branches. His vestibular schwannoma has shrunk by 0.5 cm.
Presentation and diagnosis: DB aged 71, presented to the Atlantic Lateral Skull Base Clinic in March 2008 reporting a recent history of loud noises prompting headaches. She subsequently had an audiogram which showed slight decrease in useful hearing on the right side compared to the left. An MRI (November 2007) revealed a small right-sided acoustic neuroma (18 mm × 9 mm in the axial plane). General ears, nose and throat exam was normal, other than the slight decrease in useful hearing; no tinnitus or vertigo was reported. The Unterberger stepping test revealed a moderate pulling to the right; cerebellar and oculomotor function was normal. Her facial nerve was completely normal with no facial weakness, facial twitching or facial numbness. She remained stable for a year.
Symptoms prior to treatment: In July 2009, her hearing deteriorated, to 60% of normal, and she was experiencing disequilibrium. MRI revealed slight growth in the neuroma (20 mm in longest dimension, 13 mm perpendicular to the petrous apex). A subsequent MRI in November 2009 showed further growth (20 mm × 15 mm).
Treatment and follow up: DB was referred for SRT, and this was completed June 2010. MRI in January 2011 revealed central cystic changes in tumour composition consistent with SRT. DB reported no new clinical symptoms other than further decrease in hearing on the right side.
In March 2011, new neurological symptoms emerged. Initially she described the right side of her tongue as heavy. She began to have some right-sided painful secondary paresthesia on her face in cheek area, upper and lower lips and tongue [maxillary (V2) and mandibular (V3) divisions of the trigeminal nerve] that she describes as a persistent burning sensation that is made worse by eating. She also described discomfort in her right eye and right-sided facial twitching. MRI in March 2011 showed swelling of the tumour in the right CPA consistent with SRT-induced changes. She was started on gabapentin 300 mg once daily for one week, increasing the dose to twice daily the second week, and thrice daily for the third week if tolerated.
In November of 2011 she returned. Gabapentin 300 mg once daily reduced her symptoms; however, it was associated with intolerable constipation and myalgia in the upper arms. She was weaned off gabapentin and her constipation and myalgia dissipated. The right-sided acoustic neuroma had further decreased in size, approximately 18 mm × 12 mm (May 2013) compared to 22 mm × 16 mm (April 2012), yet she continued to experience persistent chronic orofacial pain. While it is possible that DB would be refractory to other pharmacologic interventions, she has declined further interventions, despite the pain and effect on her quality of life.
The present report describes evidence for application of pain management strategies in patients with VS. A decision tool and treatment algorithm is presented to facilitate evaluation and management of patients with NP resulting from skull base disorders. A pharmacological algorithm, with primary and adjuvant treatment, summarizes pharmaceutical choice and management of NP and TN in patients with VS and can be made available in the clinic for quick review by the treating physicians. This instrument is intended to guide treatment of neuropathic/trigeminal pain in patients in acute care or ambulatory clinical settings. Essential to the comprehensive management of patients is evaluation of the effects of the intervention on quality-of-life and patient satisfaction with pain management. Patient satisfaction with pain management, using the Pain Treatment Satisfaction Scale, as well as the American Pain Society Satisfaction Survey, was influenced by effectiveness of medication on pain severity, independent of initial pain intensity, and by communication. Comparison of outcome data (self-reported pain and quality of life) will elucidate the use of standardized approaches to managing pain among patients with specific skull base etiology. The purpose of the present treatment algorithm was to develop a common scheme that may be utilized by beginning practitioners for treating this relatively uncommon, but clinically challenging, condition.
P- Reviewer: Gottschalk A, Noll-Hussong M, Tao F S- Editor: Ji FF L- Editor: A E- Editor: Liu SQ
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society.Pain Res Manag. 2007;12:13-21.
[PubMed] [DOI][Cited in This Article: ]
Chamadoira C, Cerejo A, Duarte F, Vaz R. [Trigeminal neuralgia caused by contra lateral cerebellopontine angle tumor. A case report].Neurocirugia (Astur). 2010;21:50-52.
[PubMed] [DOI][Cited in This Article: ]